{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T21:01:25Z","timestamp":1784667685430,"version":"3.55.0"},"reference-count":49,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T00:00:00Z","timestamp":1772064000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["kireports.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Kidney International Reports"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.ekir.2026.106417","type":"journal-article","created":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T16:28:04Z","timestamp":1772641684000},"page":"106417","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Sodium-Glucose Cotransporter-2\u2013inhibitors in Adult Patients With Alport Syndrome"],"prefix":"10.1016","volume":"11","author":[{"given":"Diego","family":"Toso","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valeria","family":"Cinquina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Econimo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberta","family":"Cortinovis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Letizia","family":"Zeni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vittoria","family":"Tornamb\u00e8","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Dordoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Ritelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianfranco","family":"Savoldi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cinzia","family":"Mazza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Scolari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federico","family":"Alberici","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Izzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ekir.2026.106417_bib1","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1056\/NEJMoa1806891","article-title":"Diagnostic utility of exome sequencing for kidney disease","volume":"380","author":"Groopman","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ekir.2026.106417_bib2","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1093\/ndt\/gfab019","article-title":"Clinical utility of genetic testing in early-onset kidney disease: seven genes are the main players","volume":"37","author":"Domingo-Gallego","year":"2022","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.ekir.2026.106417_bib3","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1016\/j.kint.2017.12.018","article-title":"Alport syndrome: a unified classification of genetic disorders of collagen IV \u03b1345: a position paper of the Alport Syndrome Classification Working Group","volume":"93","author":"Kashtan","year":"2018","journal-title":"Kidney Int"},{"key":"10.1016\/j.ekir.2026.106417_bib4","article-title":"Genotype-phenotype correlations for pathogenic COL4A3\u2013COL4A5 variants in X-linked, autosomal recessive, and autosomal dominant Alport syndrome","volume":"9","author":"Savige","year":"2022","journal-title":"Front Med (Lausanne)"},{"key":"10.1016\/j.ekir.2026.106417_bib5","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1681\/ASN.V114649","article-title":"X-linked Alport syndrome: natural history in 195 families and genotype- phenotype correlations in males","volume":"11","author":"Jais","year":"2000","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2026.106417_bib6","doi-asserted-by":"crossref","first-page":"178","DOI":"10.3390\/jcm8020178","article-title":"Features of autosomal recessive Alport syndrome: a systematic review","volume":"8","author":"Lee","year":"2019","journal-title":"J Clin Med"},{"key":"10.1016\/j.ekir.2026.106417_bib7","doi-asserted-by":"crossref","first-page":"2273","DOI":"10.1681\/ASN.2020071065","article-title":"Prevalence estimates of predicted pathogenic COL4A3\u2013COL4A5 variants in a population sequencing database and their implications for Alport syndrome","volume":"32","author":"Gibson","year":"2021","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2026.106417_bib8","doi-asserted-by":"crossref","first-page":"2454","DOI":"10.1016\/j.ekir.2022.08.021","article-title":"A systematic review of pathogenic COL4A5 variants and proteinuria in women and girls with X-linked Alport syndrome","volume":"7","author":"Gibson","year":"2022","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.ekir.2026.106417_bib9","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1038\/s41581-020-0329-y","article-title":"Complexities of the glomerular basement membrane","volume":"17","author":"Naylor","year":"2021","journal-title":"Nat Rev Nephrol"},{"key":"10.1016\/j.ekir.2026.106417_bib10","doi-asserted-by":"crossref","first-page":"11","DOI":"10.3389\/fped.2018.00011","article-title":"Basement membrane defects in genetic kidney diseases","volume":"6","author":"Chew","year":"2018","journal-title":"Front Pediatr"},{"key":"10.1016\/j.ekir.2026.106417_bib11","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1016\/j.humpath.2009.08.024","article-title":"Interstitial inflammation in Alport syndrome","volume":"41","author":"Jedlicka","year":"2010","journal-title":"Hum Pathol"},{"key":"10.1016\/j.ekir.2026.106417_bib12","doi-asserted-by":"crossref","DOI":"10.1038\/srep35068","article-title":"Three-dimensional electron microscopy reveals the evolution of glomerular barrier injury","volume":"6","author":"Randles","year":"2016","journal-title":"Sci Rep"},{"key":"10.1016\/j.ekir.2026.106417_bib13","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1007\/s44162-024-00036-z","article-title":"Explaining Alport syndrome\u2014lessons from the adult nephrology clinic","volume":"3","author":"Mabillard","year":"2024","journal-title":"J Rare Dis (Berlin)"},{"key":"10.1016\/j.ekir.2026.106417_bib14","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/s00467-012-2138-4","article-title":"Clinical practice recommendations for the treatment of Alport syndrome: a statement of the Alport Syndrome Research Collaborative","volume":"28","author":"Kashtan","year":"2013","journal-title":"Pediatr Nephrol"},{"key":"10.1016\/j.ekir.2026.106417_bib15","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1007\/s00467-020-04819-6","article-title":"Clinical practice recommendations for the diagnosis and management of Alport syndrome in children, adolescents, and young adults\u2013an update for 2020","volume":"36","author":"Kashtan","year":"2021","journal-title":"Pediatr Nephrol"},{"key":"10.1016\/j.ekir.2026.106417_bib16","doi-asserted-by":"crossref","DOI":"10.1093\/ndt\/gfae265","article-title":"Diagnosis, management and treatment of the Alport syndrome - 2024 guideline on behalf of ERKNet, ERA and ESPN","volume":"40","author":"Torra","year":"2025","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.ekir.2026.106417_bib17","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1053\/j.ajkd.2024.02.005","article-title":"Clinical significance of the cystic phenotype in Alport syndrome","volume":"84","author":"Zeni","year":"2024","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.ekir.2026.106417_bib18","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1053\/j.ajkd.2021.02.326","article-title":"Clinical and genetic features of autosomal dominant Alport syndrome: a cohort study","volume":"78","author":"Furlano","year":"2021","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.ekir.2026.106417_bib19","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.2215\/CJN.03120322","article-title":"Digenic Alport syndrome","volume":"17","author":"Savige","year":"2022","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2026.106417_bib20","article-title":"Novel therapies for Alport syndrome","volume":"9","author":"Chavez","year":"2022","journal-title":"Front Med (Lausanne)"},{"key":"10.1016\/j.ekir.2026.106417_bib21","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1093\/ndt\/gfz131","article-title":"New therapeutic options for Alport syndrome","volume":"34","author":"Torra","year":"2019","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.ekir.2026.106417_bib22","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1046\/j.1523-1755.2003.00779.x","article-title":"Preemptive ramipril therapy delays renal failure and reduces renal fibrosis in COL4A3-knockout mice with Alport syndrome","volume":"63","author":"Gross","year":"2003","journal-title":"Kidney Int"},{"key":"10.1016\/j.ekir.2026.106417_bib23","doi-asserted-by":"crossref","first-page":"1716","DOI":"10.1093\/ndt\/gfh219","article-title":"Antifibrotic, nephroprotective potential of ACE inhibitor vs AT1 antagonist in a murine model of renal fibrosis","volume":"19","author":"Gross","year":"2004","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.ekir.2026.106417_bib24","doi-asserted-by":"crossref","first-page":"1","DOI":"10.5402\/2012\/436046","article-title":"Safety and efficacy of the ACE-inhibitor ramipril in Alport syndrome: the double-blind, randomized, placebo-controlled, multicenter Phase III EARLY PRO-TECT Alport trial in pediatric patients","volume":"2012","author":"Gross","year":"2012","journal-title":"ISRN Pediatr"},{"key":"10.1016\/j.ekir.2026.106417_bib25","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1016\/j.kint.2019.12.015","article-title":"A multicenter, randomized, placebo-controlled, double-blind phase 3 trial with open-arm comparison indicates safety and efficacy of nephroprotective therapy with ramipril in children with Alport\u2019s syndrome","volume":"97","author":"Gross","year":"2020","journal-title":"Kidney Int"},{"key":"10.1016\/j.ekir.2026.106417_bib26","doi-asserted-by":"crossref","first-page":"2485","DOI":"10.1093\/ndt\/gfad105","article-title":"Effectiveness of renin\u2013angiotensin\u2013aldosterone system blockers in patients with Alport syndrome: a systematic review and meta-analysis","volume":"38","author":"Zeng","year":"2023","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.ekir.2026.106417_bib27","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1056\/NEJMoa2204233","article-title":"Empagliflozin in patients with chronic kidney disease","volume":"388","author":"Herrington","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ekir.2026.106417_bib28","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in patients with chronic kidney disease","volume":"383","author":"Heerspink","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ekir.2026.106417_bib29","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1093\/ndt\/gfae032","article-title":"How do SGLT2 inhibitors protect the kidney? A mediation analysis of the EMPA-REG OUTCOME trial","volume":"39","author":"Wanner","year":"2024","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.ekir.2026.106417_bib30","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1093\/ndt\/gfae203","article-title":"Empagliflozin lowers serum uric acid in chronic kidney disease: exploratory analyses from the EMPA-KIDNEY trial","volume":"40","author":"Mayne","year":"2025","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.ekir.2026.106417_bib31","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.83353","article-title":"Empagliflozin reduces podocyte lipotoxicity in experimental Alport syndrome","volume":"12","author":"Ge","year":"2023","journal-title":"eLife"},{"key":"10.1016\/j.ekir.2026.106417_bib32","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.34067\/KID.0000000000000472","article-title":"Metabolic analysis and renal protective effects of linagliptin and empagliflozin in Alport syndrome","volume":"5","author":"Ge","year":"2024","journal-title":"Kidney360"},{"key":"10.1016\/j.ekir.2026.106417_bib33","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.1093\/ndt\/gfaf051","article-title":"SGLT2 inhibitors in CKD: are they really effective in all patients?","volume":"40","author":"Romagnani","year":"2025","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.ekir.2026.106417_bib34","article-title":"Protocol and rationale for a randomized controlled SGLT2 inhibitor trial in pediatric and young adult populations with chronic kidney disease: double PRO-TECT Alport","volume":"40","author":"Gross","year":"2024","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.ekir.2026.106417_bib35","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1016\/j.ekir.2021.12.019","article-title":"Efficacy and safety of dapagliflozin in children with inherited proteinuric kidney disease: a pilot study","volume":"7","author":"Liu","year":"2022","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.ekir.2026.106417_bib36","doi-asserted-by":"crossref","first-page":"3551","DOI":"10.1007\/s00467-024-06481-8","article-title":"Efficacy and safety of dapagliflozin in children with kidney disease: real-world data","volume":"39","author":"Choi","year":"2024","journal-title":"Pediatr Nephrol"},{"key":"10.1016\/j.ekir.2026.106417_bib37","doi-asserted-by":"crossref","first-page":"2116","DOI":"10.1016\/j.ekir.2022.06.017","article-title":"Efficacy of dapagliflozin in adult autosomal recessive Alport syndrome","volume":"7","author":"Song","year":"2022","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.ekir.2026.106417_bib38","doi-asserted-by":"crossref","first-page":"1815","DOI":"10.3390\/cells10071815","article-title":"Sodium-glucose Cotransporter-2 inhibitors in patients with hereditary Podocytopathies, Alport syndrome, and FSGS: a case series to better plan a large-scale study","volume":"10","author":"Boeckhaus","year":"2021","journal-title":"Cells"},{"key":"10.1016\/j.ekir.2026.106417_bib39","doi-asserted-by":"crossref","first-page":"3490","DOI":"10.1016\/j.ekir.2024.09.014","article-title":"SGLT2-inhibition in patients with Alport syndrome","volume":"9","author":"Boeckhaus","year":"2024","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.ekir.2026.106417_bib40","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1038\/gim.2015.30","article-title":"Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology","volume":"17","author":"Richards","year":"2015","journal-title":"Genet Med"},{"key":"10.1016\/j.ekir.2026.106417_bib41","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1038\/s41431-021-00858-1","article-title":"Consensus statement on standards and guidelines for the molecular diagnostics of Alport syndrome: refining the ACMG criteria","volume":"29","author":"Savige","year":"2021","journal-title":"Eur J Hum Genet"},{"key":"10.1016\/j.ekir.2026.106417_bib42","doi-asserted-by":"crossref","first-page":"S117","DOI":"10.1016\/j.kint.2023.10.018","article-title":"KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease","volume":"105","author":"Stevens","year":"2024","journal-title":"Kidney Int"},{"key":"10.1016\/j.ekir.2026.106417_bib43","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1016\/j.kint.2020.10.031","article-title":"Characterization and implications of the initial estimated glomerular filtration rate \u201cdip\u201d upon sodium-glucose cotransporter-2 inhibition with empagliflozin in the EMPA-REG OUTCOME trial","volume":"99","author":"Kraus","year":"2021","journal-title":"Kidney Int"},{"key":"10.1016\/j.ekir.2026.106417_bib44","series-title":"R: A Language and Environment for Statistical Computing [RStudio]","year":"2025"},{"key":"10.1016\/j.ekir.2026.106417_bib45","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1053\/j.ajkd.2019.06.009","article-title":"Change in albuminuria and GFR as end points for clinical trials in early stages of CKD: a scientific workshop sponsored by the National Kidney Foundation in collaboration with the US Food and Drug Administration and European Medicines Agency","volume":"75","author":"Levey","year":"2020","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.ekir.2026.106417_bib46","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1111\/dom.14641","article-title":"Qu\u00e9telet (body mass) index and effects of dapagliflozin in chronic kidney disease","volume":"24","author":"Chertow","year":"2022","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.ekir.2026.106417_bib47","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1093\/ndt\/gfaf197","article-title":"Antiproteinuric effect of SGLT2 inhibitors in non-diabetic glomerulopathies is dependent on body mass index","volume":"41","author":"Vargas-Brochero","year":"2026","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.ekir.2026.106417_bib48","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1056\/NEJMoa2410659","article-title":"Finerenone with empagliflozin in chronic kidney disease and type 2 diabetes","volume":"393","author":"Agarwal","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ekir.2026.106417_bib49","doi-asserted-by":"crossref","first-page":"3067","DOI":"10.1016\/j.ekir.2024.07.027","article-title":"A pilot study on protective effect of Ambrisentan on proteinuria in patients with Alport syndrome","volume":"9","author":"Song","year":"2024","journal-title":"Kidney Int Rep"}],"container-title":["Kidney International Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468024926026483?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468024926026483?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T20:04:56Z","timestamp":1784664296000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2468024926026483"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":49,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["S2468024926026483"],"URL":"https:\/\/doi.org\/10.1016\/j.ekir.2026.106417","relation":{},"ISSN":["2468-0249"],"issn-type":[{"value":"2468-0249","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Sodium-Glucose Cotransporter-2\u2013inhibitors in Adult Patients With Alport Syndrome","name":"articletitle","label":"Article Title"},{"value":"Kidney International Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ekir.2026.106417","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 International Society of Nephrology. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"106417"}}